Richard Daniell - Feb 8, 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Exec. VP, European Commercial
Signature: /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell
Stock symbol: TEVA
Transactions as of: Feb 8, 2022
Transactions value $: -$119,010
Form type: 4
Date filed: 2/10/2022, 03:05 PM
Next filing: Mar 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+13.1K	+64.77%		33.4K	Feb 9, 2022	Direct	F1, F2
transaction	TEVA	Ordinary Shares	Sale	-$119K	-13.1K	-39.31%	$9.06	20.3K	Feb 9, 2022	Direct	F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-13.1K	-100%	$0.00^*	0	Feb 9, 2022	Ordinary Shares	13.1K		Direct	F1, F2, F5
transaction	TEVA	Restricted Share Units	Award	$0	+43.4K		$0.00	43.4K	Feb 8, 2022	Ordinary Shares	43.4K		Direct	F1, F2, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5	Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.
F6	Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.